Dosing & Uses
Dosage Forms & Strengths
solution for intrathecal injection
- 12mg/5mL single-dose vial
Spinal Muscular Atrophy
Indicated for spinal muscular atrophy (SMA) in children and adults
12 mg intrathecally per administration
Initial: 4 loading doses; administer the first 3 doses at 14-day intervals and the fourth dose 30 days after the third dose
Maintenance: One dose every 4 months
Also see Administration
Dosing Considerations
Laboratory tests
- Conduct the following laboratory tests at baseline and prior to each dose and as clinically needed
- Platelet count
- Prothrombin time (PT); activated partial thromboplastin time (aPTT)
- Quantitative spot urine protein testing
Dosage Forms & Strengths
solution for intrathecal injection
- 12mg/5mL single-dose vial
Spinal Muscular Atrophy
Indicated for spinal muscular atrophy (SMA) in children and adults
Safety and effectiveness have been established in children aged newborn to 17 years
12 mg intrathecally per administration
Initial: 4 loading doses; administer the first 3 doses at 14-day intervals and the fourth dose 30 days after the third dose
Maintenance: One dose every 4 months
Also see Administration
Dosing Considerations
Laboratory tests
- Conduct the following laboratory tests at baseline and prior to each dose and as clinically needed
- Platelet count
- Prothrombin time (PT); activated partial thromboplastin time (aPTT)
- Quantitative spot urine protein testing
Adverse Effects
Data are from controlled study in infants
>10%
Headache (50%)
Lower respiratory infection (43%)
Back pain (41%)
Postlumbar puncture syndrome (41%)
Upper respiratory infection (39%)
Elevated urine protein (33%)
Constipation (30%)
Atelectasis (14%)
Thrombocytopenia (11%)
1-10%
Upper respiratory tract congestion (6%)
Aspiration (5%)
Ear infection (5%)
Emergent treatment antidrug antibodies (4%)
Postmarketing Reports
Hydrocephalus
Aseptic meningitis
Hypersensitivity reactions (e.g. angioedema, urticaria, rash)
Warnings
Contraindications
None
Cautions
Coagulation
- Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some antisense oligonucleotides
- Because of risk of thrombocytopenia and coagulation abnormalities, patients may be at increased risk of bleeding complications
- Obtain platelet count and coagulation laboratory testing at baseline and prior to each administration and as clinically needed
Renal toxicity
- Nusinersen is present in and excreted by the kidney
- Renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides
- Conduct quantitative spot urine protein testing (preferably using a first-morning urine specimen) at baseline and prior to each dose
- For urinary protein concentration >0.2 g/L, consider repeat testing and further evaluation
Pregnancy
Pregnancy
There are no adequate data on the developmental risk associated with use in pregnant women
No adverse effects on embryofetal development were observed in animal studies in which nusinersen was administered by subcutaneous injection to mice and rabbits during pregnancy
Lactation
Unknown if distributed in human breast milk; detected in milk of lactating mice when administered by subcutaneous injection
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
An antisense oligonucleotide (ASO) designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency
Using in vitro assays and studies in transgenic animal models of SMA, nusinersen was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein
Absorption
Trough plasma levels relatively low, compared to trough CSF concentration
Peak plasma time: 1.7-6 hr
Distribution
CSF and peripheral tissues (eg, skeletal muscle, liver, kidney)
Metabolism
Metabolized via exonuclease (3’- and 5’)-mediated hydrolysis
Not a substrate for, or inhibitor, or inducer of CYP450 enzymes
Elimination
Half-life: 135-177 days (CSF); 63-87 days (plasma)
Excretion: primary route of elimination is likely by urinary excretion; at 24 hr, only 0.5% of the administered dose was recovered in the urine
Administration
Intrathecal Preparation
Obtain laboratory testing before each dose (see Dosing)
Use aseptic technique
Each vial is intended for single dose only
Store drug in the carton in a refrigerator until time of use
Allow the vial to warm to room temperature (25°C/77°F) prior to administration; do not use external heat sources
Inspect vial content for particulate matter and discoloration prior to administration; do not administer if visible particulates are observed or if the liquid in the vial is discolored (should be clear and colorless)
Use of external filters not required
Withdraw 12 mg (5 mL) from the single-dose vial into a syringe and discard unused contents (ie, overfill) of the vial
Administer within 4 hr of removal from vial
Intrathecal Administration
For intrathecal use only
Consider sedation as indicated by the clinical condition of the patient
Consider ultrasound or other imaging techniques to guide intrathecal administration of, particularly in younger patients
Prior to administration, remove 5 mL of cerebrospinal fluid
Administer as an intrathecal bolus injection over 1-3 minutes using a spinal anesthesia needle
Do not administer in areas of the skin where there are signs of infection or inflammation
Missed dose
- If a loading dose is delayed or missed, administer as soon as possible, with at least 14-days between doses and continue dosing as prescribed
- If a maintenance dose is delayed or missed, administer as soon as possible and continue dosing every 4 month
Storage
Store in a refrigerator between 2-8°C (36-46°F) in the original carton to protect from light
Do not freeze
Should be protected from light and kept in the original carton until time of use
If no refrigeration is available, may be stored in its original carton, protected from light at ≤30°C (86°F) for up to 14 days
Prior to administration, unopened vials can be removed from and returned to the refrigerator, if necessary
If removed from the original carton, the total combined time out of refrigeration should not exceed 30 hours at a temperature that does not exceed 25°C (77°F)
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Spinraza (PF) intrathecal - | 12 mg/5 mL vial | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.